New gene targets for treating adult blood cancer

New gene targets for treating adult blood cancer
Effect of palbociclib on ATLL tumors in mice. ATLL tumors grafted into mice were subjected to three treatments and compared to a control (far left). Treatment with palbociclib reduced the size of tumors (center left), while treatment with everolimus also reduced the size of the tumors (centre right). However, treatment with both drugs in combination significantly reduced tumor size (far right). Credit: Takashi Ishio, et al. Blood

Hokkaido University scientists have identified new targets for treating an aggressive form of adult leukemia with existing drugs. The findings were published in the journal Blood.

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of blood cancer that is linked to a viral infection. Currently available chemotherapies are not particularly effective in treating the disease, which has a long-term survival rate of only 20%. Much research has been done to explore the molecular pathways and gene mutations involved in this cancer, but these vary between patients, making it difficult to develop effective treatments.

Hokkaido University hematologist Masao Nakagawa and colleagues in Japan, the US and France used the CRISPR-Cas9 gene editing technology to inactivate thousands of genes in several ATLL cell lines. Their aim was to pinpoint genes and pathways that could be targeted with drugs to kill ATLL cells. The process led to the identification of 1,278 genes that were essential for the survival and proliferation of ATLL cells. They then narrowed down this number to nine genes for more detailed investigations.

Among these, one gene proved particularly promising as a drug target. The gene CDK6 encodes an enzyme that activates . The scientists found that inactivating the enzyme with a drug currently used to treat breast cancer, called palbociclib, stopped and caused in some, but not all, of the tested ATLL cell lines.

The cell lines that were resistant to the drug had a mutation in a gene called TP53, which under normal circumstances is involved in inhibiting and development. These cells died when treated with palbociclib together with an activator of mutant TP53; a drug that is currently used to treat a type of blood cancer called myelodysplastic syndrome.

Importantly, the researchers also found that combining palbociclib with the drug everolimus, which is used to treat kidney and , also killed ATLL cells, including those with TP53 mutations. The drug combination also significantly reduced tumor growth and had minimal side effects when tested in mice with grafted ATLL tumors. Everolimus inhibits a , called mTORC1, which is involved in for cell growth and proliferation.

"Our study reveals CDK6 as an attractive target for treating ATLL," says Nakagawa. "However, we also discovered that loss of TP53 function in some ATLL leads to resistance to the CDK6 inhibitor, palbociclib. Given this finding, researchers should consider the status of TP53 in future clinical trials of palbociclib in ATLL."

Explore further

Immunotherapy treats aggressive form of lymphoma

More information: Takashi Ishio et al, Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma, Blood (2021). DOI: 10.1182/blood.2021012734
Journal information: Blood

Citation: New gene targets for treating adult blood cancer (2022, March 31) retrieved 1 July 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors